Neuromodulation, the science of altering brain and nervous system activity through carefully applied stimulation, is reshaping modern healthcare. By addressing conditions where traditional treatments often fall short, this field offers a path to personalized and non-invasive solutions for complex neurological and mental health challenges. With advances in neuroscience, AI, and medical technology converging, neuromodulation is opening doors to predictive, preventative, and highly tailored care.
In this context, Cyprus’s Chief Scientist, Demetris Skourides, recently visited SOZO Brain Center to experience firsthand how a local pioneer is collaborating with Israel-based BrainSpace to set global standards in neuromodulation research, AI-guided therapy, and clinical innovation.
Cutting-Edge Technology and First-of-Its-Kind AI Platform
At SOZO, Mr. Skourides was introduced to a technological ecosystem that is unlike anything currently available worldwide. The center has designed exclusive neuromodulation treatment protocols that integrate directly into BrainSpace’s advanced neurotechnology platform — a breakthrough system powered by agentic AI. This platform serves a dual role: it identifies biomarkers and tracks changes before and after neuromodulation therapy, while simultaneously functioning as an intelligent decision-support tool to help clinicians select the most effective brain-stimulation strategies for each patient.
Conditions such as Parkinson’s disease, Alzheimer’s, dementia, autism, depression, anxiety, and other neurodegenerative or treatment-resistant disorders are the focus of this work. During his visit, Mr. Skourides even tested SOZO’s AI-enabled helmet, known as Brain Sensei, observing how it collects real-time brain activity and translates the data into actionable guidance for physicians.
Research Driving Global Recognition
Behind these technological advances is SOZO’s Research Department, a multidisciplinary team of neuroscientists and medical specialists who are committed to advancing the science of brain stimulation. Their findings have already been showcased at world-leading gatherings, including the World Congress of Neurology and the International Neuromodulation Society World Congress, and future results will be published in top-tier scientific journals. These contributions are helping to place Cyprus firmly on the global research map.
Training a Global Network of Physicians
SOZO is not only a research hub but also an educational leader. More than 150 doctors across 14 countries — from the USA and Germany to Singapore, Australia, and beyond — have been trained in its methodologies. Among them, over 60 have achieved SOZO Fellowship certification, granting them the license to apply the organization’s proprietary treatment protocols in their own practices. Collectively, this physician network has treated over 3,500 patients worldwide, achieving success rates above 70%, far surpassing typical outcomes of conventional medical care.
To scale this expertise further, SOZO is investing in three pillars of expansion: a Clinical Trials Centre meeting UK and US standards to validate neuromodulation’s efficacy, a CME-accredited e-learning platform to standardize physician training globally, and Train-the-Trainer programs designed to build regional hubs of neuromodulation excellence.
Expanding Through International Clinics
In parallel with education, SOZO is extending its reach through international partnership clinics. New centers in Berlin, Vienna, Melbourne, and Athens are already applying SOZO’s Functional Network-Oriented Neuromodulation (FNON) Protocol, positioning Cyprus not just as the birthplace of this innovation, but as the global reference center for neuromodulation-based care.
Protecting Innovation Through Intellectual Property
SOZO’s rapid rise is anchored by a robust intellectual property portfolio. Its proprietary rights cover the FNON Protocol itself, along with physician manuals, treatment procedures, diagnostic reporting systems, patient education materials, e-learning programs, and internationally registered trademarks. By 2026, SOZO also plans to introduce patentable innovations in neuromodulation device development, ensuring its leadership in both clinical and technological domains.
Cyprus’s Bold Role in Healthcare Innovation
The presence of Chief Scientist Demetris Skourides alongside BrainSpace CEO Yair Levy underscored the importance of SOZO’s work to Cyprus’s broader innovation strategy. Their visit confirmed that Cyprus is making decisive moves to become a regional and global leader in advanced healthcare solutions. With its combination of predictive AI, pioneering treatment protocols, and international partnerships, SOZO Brain Center is not only advancing brain health but also showcasing how Cyprus can export world-class healthcare innovation and contribute to solving some of the most urgent neurological and psychiatric challenges of our time.care technologies. With predictive AI, pioneering protocols, and an expanding global network, SOZO Brain Center is redefining brain health, elevating Cyprus’s role in global medical innovation, and offering new hope to patients worldwide seeking effective, drug-free treatments for some of the most challenging neurological conditions.
